Hyperspectral imaging in systemic sclerosis-associated Raynaud phenomenon

被引:1
|
作者
Teaw, Shannon [1 ]
Gupta, Akash [1 ]
Williams, Alyssa [1 ]
Wilson, F. Perry [2 ,3 ]
Sumpio, Brandon J. J. [4 ]
Sumpio, Bauer E. E. [5 ]
Hinchcliff, Monique [1 ,2 ]
机构
[1] Yale Sch Med, Dept Med, Sect Rheumatol Allergy & Immunol, Anlyan Ctr, 300 Cedar St, POB 208031, New Haven, CT 06520 USA
[2] Yale Sch Med, Dept Med, Clin & Translat Res Accelerator, New Haven, CT 06520 USA
[3] Yale Sch Med, Dept Internal Med, Sect Nephrol, New Haven, CT USA
[4] Massachusetts Gen Hosp, Div Vasc & Endovasc Surg, Boston, MA USA
[5] Yale Sch Med, Dept Surg, Div Vasc Surg, New Haven, CT USA
基金
美国国家卫生研究院;
关键词
Systemic sclerosis; Scleroderma; Hyperspectral imaging; Raynaud phenomenon; Patient-reported outcome instruments; Imaging; Outcomes; Digital ulcers; Raynaud condition score; Cochin hand function scale; PERIPHERAL-BLOOD PERFUSION; SPECKLE CONTRAST ANALYSIS; CLASSIFICATION CRITERIA; ENDOTHELIAL DYSFUNCTION; AMERICAN-COLLEGE; CLINICAL-TRIALS; CONDITION SCORE; BINDING-SITES; SKIN; MICROCIRCULATION;
D O I
10.1186/s13075-023-02990-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/purposeLack of robust, feasible, and quantitative outcomes impedes Raynaud phenomenon (RP) clinical trials in systemic sclerosis (SSc) patients. Hyperspectral imaging (HSI) non-invasively measures oxygenated and deoxygenated hemoglobin (oxyHb and deoxyHb) concentrations and oxygen saturation (O-2 sat) in the skin and depicts data as oxygenation heatmaps. This study explored the potential role of HSI in quantifying SSc-RP disease severity and activity.MethodsPatients with SSc-RP (n = 13) and healthy control participants (HC; n = 12) were prospectively recruited in the clinic setting. Using a hand-held camera, bilateral hand HSI (HyperMed (TM), Waltham, MA) was performed in a temperature-controlled room (22 degrees C). OxyHb, deoxyHb, and O-2 sat values were calculated for 78-mm(2) regions of interest for the ventral fingertips and palm (for normalization). Subjects underwent a cold provocation challenge (gloved hand submersion in 15 degrees C water bath for 1 min), and repeated HSI was performed at 0, 10, and 20 min. Patients completed two patient-reported outcome (PRO) instruments: the Raynaud Condition Score (RCS) and the Cochin Hand Function Scale (CHFS) for symptom burden assessment. Statistical analyses were performed using the Mann-Whitney U test and a mixed effects model (Stata, College Station, TX).ResultsNinety-two percent of participants were women in their 40s. For SSc-RP patients, 69% had limited cutaneous SSc, the mean +/- SD SSc duration was 11 +/- 5 years, and 38% had prior digital ulcers-none currently. Baseline deoxyHb was higher, and O-2 sat was lower, in SSc patients versus HC (p < 0.05). SSc patients had a greater decline in oxyHb and O-2 sat from baseline to time 0 (after cold challenge) with distinct rewarming oxyHb, O-2 sat, and deoxyHb trajectories versus HCs (p < 0.01). There were no significant correlations between oxyHb, deoxyHb, and O-2 sat level changes following cold challenge and RCS or CHFS scores.ConclusionHyperspectral imaging is a feasible approach for SSc-RP quantification in the clinic setting. The RCS and CHFS values did not correlate with HSI parameters. Our data suggest that HSI technology for the assessment of SSc-RP at baseline and in response to cold provocation is a potential quantitative measure for SSc-RP severity and activity, though longitudinal studies that assess sensitivity to change are needed.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] The contribution of platelets to the pathogenesis of Raynaud's phenomenon and systemic sclerosis
    Pauling, J. D.
    O'Donnell, V. B.
    Mchugh, N. J.
    PLATELETS, 2013, 24 (07) : 503 - 515
  • [42] Author Correction: Raynaud phenomenon and digital ulcers in systemic sclerosis
    Michael Hughes
    Yannick Allanore
    Lorinda Chung
    John D. Pauling
    Christopher P. Denton
    Marco Matucci-Cerinic
    Nature Reviews Rheumatology, 2021, 17 : 246 - 246
  • [43] EFFECT OF SARPOGRELATE FOR RAYNAUD'S PHENOMENON SECONDARY TO SYSTEMIC SCLEROSIS
    Makino, T.
    Jinnin, M.
    Kajihara, I.
    Makino, K.
    Ihn, H.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2014, 32 (02) : S79 - S79
  • [44] Angiogenic factors in autoimmune Raynaud's phenomenon and systemic sclerosis
    Black, C
    JOURNAL OF VASCULAR RESEARCH, 1999, 36 (02) : 169 - 169
  • [45] Botulinum toxin in the treatment of Raynaud phenomenon in patients with systemic sclerosis: a systemic review
    Cai Ruyi
    Yi Zixi
    Li Ting
    Mu Rong
    中华医学杂志英文版, 2022, 135 (09) : 1133 - 1134
  • [46] Botulinum toxin in the treatment of Raynaud phenomenon in patients with systemic sclerosis: a systemic review
    Cai, Ruyi
    Yi, Zixi
    Li, Ting
    Mu, Rong
    CHINESE MEDICAL JOURNAL, 2022, 135 (09) : 1133 - 1134
  • [47] Systemic Sclerosis-Associated Myopathy: How to Treat
    Selva-O'Callaghan, A.
    Guillen-Del-Castillo, A.
    Gil-Vila, A.
    Trallero-Araguas, E.
    Matas-Garcia, A.
    Milisenda, J. C.
    Pinal-Fernandez, I.
    Simeon-Aznar, C.
    CURRENT TREATMENT OPTIONS IN RHEUMATOLOGY, 2023, 9 (04) : 151 - 167
  • [48] TAKO-TSUBO CARDIOMYOPATHY ASSOCIATED WITH SYSTEMIC SCLEROSIS: A SIGN OF MYOCARDIAL RAYNAUD'S PHENOMENON?
    Goff, Iain
    Reynolds, Gary
    Grove, Matthew
    RHEUMATOLOGY, 2013, 52 : 62 - 63
  • [49] Systemic sclerosis-associated interstitial lung disease
    Scallan, Ciaran J.
    Collins, Bridget F.
    Raghu, Ganesh
    CURRENT OPINION IN PULMONARY MEDICINE, 2020, 26 (05) : 487 - 495
  • [50] Systemic Sclerosis-Associated Myopathy: How to Treat
    A. Selva-O’Callaghan
    A. Guillen-Del-Castillo
    A. Gil-Vila
    E. Trallero-Araguás
    A. Matas-García
    J. C. Milisenda
    I. Pinal-Fernández
    C. Simeón-Aznar
    Current Treatment Options in Rheumatology, 2023, 9 : 151 - 167